Skip to content
Menu

Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $205

Benzinga Newsdesk 2 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Cantor Fitzgerald analyst Olivia Brayer Saunders maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price target from $290 to $205.

Cantor Fitzgerald analyst Olivia Brayer Saunders maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price target from $290 to $205.

Read at benzinga.com